President Donald Trump said Friday that he’s hopeful to have a coronavirus vaccine on the market by the end of the year or shortly thereafter.
The president was updating his Operation Warp Speed project during remarks in the Rose Garden Friday.
Trump said the project’s objective is to “finish developing and then to manufacture and distribute a proven coronavirus vaccine as fast as possible,” stressing that he would like to see it happen before the end of the year.
“We think we’re going to have some very good results coming out very quickly,” he said.
Moncep Slaoui, a former pharmaceutical executive who Trump has tapped to serve as the administration’s virus czar, said that early trial data suggests that a few hundred million doses of vaccine will be delivered by late 2020.
Trump also reiterated that he wants to see states move forward with reopening their economies.
“Vaccine or no vaccine, we are back,” Trump said.
Subscribe to our YouTube channel: https://bit.ly/2TwO8Gm
QUICKTAKE ON SOCIAL:
Follow QuickTake on Twitter: twitter.com/quicktake
Like QuickTake on Facebook: facebook.com/quicktake
Follow QuickTake on Instagram: instagram.com/quicktake
Subscribe to our newsletter: https://bit.ly/2FJ0oQZ
Email us at quicktakenews@gmail.com
QuickTake by Bloomberg is a global news network delivering up-to-the-minute analysis on the biggest news, trends and ideas for a new generation of leaders.
In This Story: GlaxoSmithKline
GlaxoSmithKline plc (GSK) is a British multinational pharmaceutical company headquartered in Brentford, England.
Established in 2000, by a merger of Glaxo Wellcome and SmithKline Beecham, GSK was the world’s sixth largest pharmaceutical company according to Forbes as of 2019, after Pfizer, Novartis, Roche, Sanofi, and Merck & Co.
GSK is the tenth largest pharmaceutical company and #296 on the 2019 Fortune 500, ranked behind other pharmaceutical companies including China Resources, Johnson & Johnson, Roche, Sinopharm, Pfizer, Novartis, Bayer, Merck, and Sanofi.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. As of August 2016, it had a market capitalisation of £81 billion (about US$107 billion), the fourth largest on the London Stock Exchange. It has a secondary listing on the New York Stock Exchange.
The company developed the first malaria vaccine, RTS,S, which it said in 2014, it would make available for five percent above cost. Legacy products developed at GSK include several listed in the World Health Organization‘s List of Essential Medicines, such as amoxicillin, mercaptopurine, pyrimethamine, and zidovudine.
In 2012, GSK pleaded guilty to promotion of drugs for unapproved uses, failure to report safety data, and kickbacks to physicians in the United States and agreed to pay a US$3 billion (£1.9bn) settlement. It was the largest health-care fraud case to date in that country and the largest settlement by a drug company.
